Glenmark Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for Telmisartan and Hydrochlorothiazide tablets, used to treat high blood pressure (hypertension). The approved products are a generic version of Boehringer Ingelheim Pharmaceuticals Inc’s Micardis HCT tablets. Quoting IQVIA sales data for the 12-month period ending January 2019, Glenmark said the Micardis HCT tablets market achieved annual sales of approximately $40.6 million. The company’s stock gained 0.88 per cent at ₹604.35 on the NSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.